Down Syndrome (DS) is the most common genetic cause of intellectual disability, where an extra copy of human chromosome 21 (HSA21) produces differential genome-wide DNA methylation profiles. Although DNA methylation has been examined across the genome at select regulatory regions in a variety of DS tissues and cells, the differentially methylated regions (DMRs) have yet to be examined in an unbiased sequencing-based approach. Here, we present the first analysis of DMRs from whole-genome bisulfite sequencing (WGBS) data of human DS and matched control brain, specifically frontal cortex. While we did not observe global differences in DNA methylation, we identified 3,152 DMRs across the entire genome, which were primarily hypermethylated in DS. DS-DMRs were significantly enriched at CpG islands and deenriched at specific gene body and regulatory regions. Functionally, the hypermethylated DSDMRs were enriched for one-carbon metabolism, membrane transport, and glutamatergic synaptic signaling, while the hypomethylated DMRs were enriched for proline isomerization, glial immune response, and apoptosis. Furthermore, in a cross-tissue comparison to previous studies of DNA methylation from diverse DS tissues and reference epigenomes, hypermethylated DS DMRs showed a strong cross-tissue concordance, while a more tissue-specific pattern was observed for the hypomethylated DS DMRs. Overall, this approach highlights the utility of applying low-coverage WGBS to clinical samples and demonstrates novel gene pathways potentially relevant to DS treatments. These results also provide new insights into the genomewide effects of genetic alterations on DNA methylation profiles indicative of altered neurodevelopment.
Introduction
Down Syndrome (DS), which is also referred to as Trisomy 21 , results from an extra copy of human chromosome 21 (HSA21). DS is the most common genetic cause of intellectual disability and also the most common chromosomal aneuploidy in live-births, affecting approximately 1 in 691 in the United States (1) . Maternal age is a risk factor for DS with a noticeable increase occurring in mothers greater than 35 years old (2) . The prevalence of live births with DS has increased by 31% from 1979 through 2003 (3) . Life expectancy for people with DS has increased rapidly from 10 years in 1960 to 47 years in 2007 (4) . Overall, individuals with DS represent a substantial and growing part of the population.
DS is characterized by distinct phenotypic traits, which include intellectual disability, facial dysmorphisms, short stature, congenital heart defects, and immune system abnormalities (5) . Notably, DS is also associated with an increased risk for childhood leukemia and early onset Alzheimer's disease. An understanding of the molecular mechanisms downstream of the genetic underpinnings of DS will also enable future therapeutic interventions as well as an understanding of the associated traits and diseases in the non-DS population.
Although DS is the result of the increased copy number of a single chromosome, it affects the regulation of gene expression at a genome-wide level in a wide variety of tissues (6, 7) . While there is an increase in global gene expression from HSA21 in DS patients, not all HSA21 genes are differentially expressed, and differential gene expression is observed genome-wide across all chromosomes (8) (9) (10) (11) ). An examination of fibroblasts from monozygotic twins discordant for DS revealed that differential gene expression occurred in distinct chromosomal domains that correlated with late DNA replication domains and lamina-associated domains (LADs) (12) . While the positioning of the LADs was not altered, H3K4me3, a histone modification associated with active promoters, was altered within the DS-associated chromosomal domains. Further investigation into fetal skin fibroblasts from additional sets of monozygotic twins uncovered differential DNA CpG methylation outside of HSA21 (13) . These regions were predominantly hypermethylated in DS, and mapped to genes involved in embryonic organ morphogenesis. Differentiation of the DS fibroblasts into induced pluripotent stem cells (iPSC) revealed that select DS DMRs were maintained and correlated with differential gene expression and increased expression of the DNA methyltransferases DNMT3B and DNMT3L. Thus, the genome-wide differences seen in DS tissues are correlated with epigenetic modifications that may be responsible, in part, for the establishment and/or maintenance of differential expression of genes outside of HSA21 in DS.
Investigation into the epigenetic mechanisms of DS have primarily focused on DNA methylation, where genome-wide differences in CpG methylation have been observed in a variety of DS tissues (7) . Given the tissue specific nature of epigenetic modifications, the differences have primarily been examined in cells and tissues relevant to DS phenotypes. For example, differential methylation has been observed in blood cells (14, 15) and fetal liver mononuclear cells (16) , which are responsible for immune functions, and these differences mapped to genes involved in the development of these cell types. Genome-wide differences have also been observed in buccal epithelial cells, where some of differences were observed in genes related to cell adhesion, protein phosphorylation, and neurodevelopment (17) . Notably, like neurons, buccal epithelial cells are derived from the ectoderm and demonstrate a more similar methylation pattern to the brain than blood (18) . Overall, the differential CpG methylation typically appears to be related to genes involved in early developmental processes that are relevant to the cell type assayed.
While the CpG sites with differential methylation in DS are primarily specific to the tissue and cell types examined, most aberrantly methylated CpG sites in DS are hypermethylated. For example, an examination of DS placenta revealed global hypermethylation across all autosomes (19) . Placental gene expression from HSA21 was upregulated, but genes outside of HSA21 with promoter hypermethylation in DS were down-regulated. Interestingly, the DS-differential genes had functions related to the immune system and neurodevelopment. Global CpG hypermethylation (<1% difference) was also present in both fetal (mid-gestation cerebrum) and adult (cerebellar folial cortex and frontal cortex) DS brain tissues as well as sorted neurons (NeuN+ nuclei) and glia (NeuN-nuclei) from adult frontal cortex (20) . Only sorted T-lymphocytes (CD3+) from adult DS peripheral blood failed to demonstrate global hypermethylation. While global hypermethylation was observed in fetal and adult brain tissues and cells, the majority of DS differentially methylated CpGs were specific to the tissue/cell type assayed. DS differentially methylated CpGs in brain tissues/cells as well as T cells were enriched for pathways related to their development and function. Another examination of DS fetal brain tissue (frontal and temporal cortex) observed a trend of modest global hypermethylation (0.3%) as well as hypermethylation of the clustered protocadherins, which are critical to neurodevelopment (21) . Interestingly, two separate studies of DS fetal frontal cortex have found that while significant DSdifferential CpGs located on HSA21 displayed a balance of hypermethylation and hypomethylation, the significant CpGs across all other chromosomes were predominantly hypermethylated (21, 22) . The DS differentially methylated CpGs belonged to genes involved in ubiquitin mediated proteolysis and Alzheimer's disease pathways (22) . Taken together, the differences in CpG methylation observed across a variety of DS cells/tissues are not only relevant to early developmental events but also appear to be maintained into adulthood.
While the human DS studies discussed above have demonstrated genome-wide a characteristic signature of CpG hypermethylation in multiple DS tissues and cells, they have all made use of targeted assays that do not cover the whole-genome but rather examine a large number of distinct and previously characterized regulatory elements. These methods do include regulatory elements representative of methylation across the entire genome nor do they allow for the discovery of epigenetic changes to novel regulatory regions unique to DS. Therefore, we sought to comprehensively examine the methylomic signature of DS using WGBS and a systems biology approach to understand the impact of DNA methylation in DS cortex. This analysis confirms and expands on the DS epigenomic literature by identifying a more comprehensive set of differentially methylated regions (DMRs) in post-mortem DS brain. Furthermore, a crossanalysis of our WGBS results with those from diverse DS tissues provides convergent evidence for reproducible genome-wide epigenetic changes associated with trisomy 21 in DS.
Results

WGBS analysis of DNA methylation in DS cortex reveals an abundance of hypermethylated DMRs
WGBS was performed on DNA isolated from 4 male DS and 5 male control post-mortem Broadman area 9 (BA9) samples (Supplementary Table 1 and Supplementary File 1) previously described (23) . None of the DS patients were above the age of 25 and thus are less likely to be confounded by the methylomic signature of early onset Alzheimer's disease risk of DS. Copy number analysis of the aligned WGBS data confirmed total trisomy 21 in DS and the absence of chromosomal aneuploidies in control samples (Supplementary Figure 1) . Principal component analysis (PCA) of the average methylation over 20 kb bins of CpG sites or CpG islands alone revealed no differences in large-scale DNA methylation profiles (Supplementary Figure 2) . Furthermore, there were no significant differences in CpG or CpH methylation at the global level.
Given the lack of global differences in DNA methylation, we next examined locus-specific differentially methylated regions (DMRs), which represent sequences spanning several hundred to a few thousand base pairs. DMRs were identified through a smoothing approach that weights CpG sites based on their coverage (Supplementary Figure 3) . CpGs with correlated methylation values were grouped into DMRs, and a region statistic for each DMR was estimated (Methods). Statistical significance of each region was determined by permutation using a pooled null distribution. There were 9,376,534 CpG sites covered by WGBS in all samples, and 100,779 testable background regions of potential differential methylation of at least 5 CpGs (Supplementary Table 2 ). From this testable background, 3,152 significant (permutation p < 0.05) DMRs were identified that distinguished DS from control brain (Figure 1 and Supplementary  Table 3) . A greater number of DS-DMRs were hypermethylated (2,420) than hypomethylated (732). Interestingly, the relative abundance of hypermethylation was consistent across every chromosome (Supplementary Figure 4) . A modified approach was also utilized to examine largerscale blocks of differential methylation, where out of 87 testable blocks (Supplementary Table  4 ), 2 blocks with significant (permutation p<0.05) differential methylation were identified (Supplementary Table 5 and Supplementary Figure 5) . These significant blocks were not in direct proximity to protein coding genes.
Cross-tissue analyses uncover significant overlap of a subset of WGBS identified DS-DMRs
To compare the DMRs identified in our WGBS study to other genomic methylome studies in DS, we utilized previously published findings from a pan-tissue DS meta-analysis of adult brain, fetal brain, placenta, adult buccal epithelium, and adult blood samples, which identified 25 genes (24 hypermethylated and 1 hypomethylated) with differential methylation (7). We observed a significant enrichment (Fisher's exact test, p=0.0005, Odds Ratio = 5.5) for 8 genes mapping to 12 hypermethylated DMRs in our WGBS identified DS-DMRs: GLI4 (GLI Family Zinc Finger 4), ZNF837 (Zinc Finger Protein 837), RYR1 (Ryanodine Receptor 1), LRRC24 (Leucine Rich Repeat Containing 24), CELSR3 (Cadherin EGF LAG Seven-Pass G-Type Receptor), RUNX1 (Runt Related Transcription Factor 1), UNC45A (Unc-45 Myosin Chaperone A), and RFPL2 (Ret Finger Protein Like 2). Notably, these pan-tissue DS-DMR associated genes were previously identified based on differential methylation of single CpG sites and are consistently identified here as larger scale DMRs. epigenomes (http://egg2.wustl.edu/roadmap/web_portal/chr_state_learning.html) (25) . The genomic association tester (GAT; (https://github.com/AndreasHeger/gat) (55) was used for sequence specific overlap, relative to background regions and corrected for GC content, with regulatory features and the other datasets, where the other data sets were lifted over from hg19 to hg38. 100,000 permutations were utilized for all GAT analyses. Gene symbol specific overlap was performed using GeneOverlap (https://github.com/shenlab-sinai/geneoverlap). The Hypergeometric Optimization of Motif EnRichment (HOMER) toolset (http://homer.ucsd.edu/homer/motif/) was used to identify enriched transcription factor binding sites via the findMotifsGenome.pl script, where the region size was set to size given, the normalization was set to CpG content, and the background regions were broken up to the average size of the target regions (56) . 
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